H3N2 is a subtype of influenza A, one of the most common flu viruses circulating in humans. It’s responsible for a large share of seasonal flu hospitalizations each year and is known for mutating quickly, which makes it a moving target for vaccines. If you’ve had the flu in recent years, there’s a good chance H3N2 was the cause.
How H3N2 Is Classified
The “H” and “N” in H3N2 refer to two proteins on the virus’s surface: hemagglutinin (H) and neuraminidase (N). These proteins are what your immune system recognizes and responds to. Hemagglutinin helps the virus latch onto and enter cells in your respiratory tract, while neuraminidase helps newly made copies of the virus break free from infected cells and spread to new ones. The numbers simply identify which version of each protein the virus carries.
All influenza A viruses are classified this way. H1N1 (the strain behind the 2009 pandemic) is the other major subtype that regularly infects people. H3N2 has been circulating in humans since the 1968 pandemic and tends to mutate its surface proteins faster than H1N1, which is why flu seasons dominated by H3N2 often hit harder overall.
Symptoms and How It Spreads
H3N2 causes the same symptoms as other types of flu: fever, cough, sore throat, body aches, fatigue, and sometimes vomiting or diarrhea (more common in children). Symptoms typically appear one to four days after exposure. Most adults become contagious about a day before symptoms start and remain infectious for roughly five to seven days after getting sick. Children, people with weakened immune systems, and those who are severely ill can shed the virus for 10 days or longer.
The virus spreads primarily through respiratory droplets when an infected person coughs, sneezes, or talks. You can also pick it up by touching a contaminated surface and then touching your face, though droplet transmission is the main route.
H3N2 Severity Compared to Other Flu Strains
H3N2 sends more people to the hospital than other flu types in a typical season, but the picture is more nuanced than raw numbers suggest. A CDC study comparing outcomes across flu subtypes found that people hospitalized with H1N1 were actually 42% more likely to end up in the ICU and 25% more likely to die than those hospitalized with H3N2. Influenza B patients were also 18% more likely to die than H3N2 patients once hospitalized.
So H3N2 infects more people and causes more total hospitalizations, but on a case-by-case basis among hospitalized patients, H1N1 and influenza B tend to cause more severe outcomes. The reason H3N2 drives so much overall burden is that it spreads efficiently and its frequent mutations mean prior immunity wears off faster.
Who Faces the Highest Risk
Serious complications from H3N2 can happen to anyone, but certain groups face substantially higher risk. Adults 65 and older are especially vulnerable, as are children younger than 5 (particularly those under 2). Pregnant women, people with a BMI of 40 or higher, and anyone with chronic conditions like asthma, diabetes, or heart disease also face elevated risk.
Complications can include bacterial pneumonia, ear infections, sinus infections, and flare-ups of existing conditions. For someone with congestive heart failure or poorly controlled diabetes, a bout of H3N2 can destabilize their underlying condition in ways that outlast the flu itself.
Testing and Diagnosis
If you visit a clinic with flu symptoms, you’ll likely be offered a rapid influenza diagnostic test, which involves a nasal swab and returns results in about 15 minutes. These tests are convenient but imperfect. Their sensitivity sits around 50 to 70%, meaning they miss a significant number of true infections. The FDA now requires newer rapid tests to achieve at least 80% sensitivity. Specificity is high (95 to 99%), so a positive result is almost always accurate, but a negative result during flu season doesn’t necessarily rule out infection.
A more precise option is a molecular test called RT-PCR, which detects the virus’s genetic material and is considered the gold standard. Your doctor may order this if your rapid test is negative but flu is still strongly suspected, or if the result would change your treatment plan.
Treatment and Antiviral Resistance
Antiviral medications work best when started within 48 hours of symptom onset. Nearly all recently circulating H3N2 strains remain susceptible to the two main classes of antivirals currently recommended: neuraminidase inhibitors (the class that includes the most commonly prescribed flu antiviral) and a newer drug that works by blocking the virus’s ability to replicate its genetic material. An older class of antivirals called adamantanes is no longer recommended because virtually all circulating influenza A strains, including H3N2, are resistant to them.
For most healthy adults, flu resolves on its own within one to two weeks with rest and fluids. Antivirals can shorten the illness by roughly a day and reduce the risk of complications, which is why they’re most often prescribed for people in high-risk groups or those with severe symptoms.
How the Vaccine Keeps Up
H3N2’s rapid mutation rate is the main reason flu vaccines need to be updated every year. The World Health Organization reviews circulating strains and recommends specific virus candidates for vaccine production months before each flu season begins. For the 2025-2026 U.S. season, the H3N2 component is based on viruses collected in 2023: an A/Croatia strain for egg-based vaccines and an A/District of Columbia strain for cell-based and recombinant vaccines.
The reason two different strains are used comes down to manufacturing. Viruses grown in eggs can pick up small mutations that make them slightly different from what’s actually circulating. Cell-based and recombinant vaccines avoid this problem, which is why they use a strain that more closely matches wild H3N2 viruses. In seasons where H3N2 dominates, vaccine effectiveness tends to be lower than in H1N1-dominant seasons, precisely because H3N2 mutates so quickly that even a well-matched vaccine can lose ground by the time flu peaks. Getting vaccinated still reduces your risk of hospitalization, even when the match isn’t perfect.